Cancer Therapeutics

癌症治疗

• 批准号: 10411081
• 负责人: NATHANAEL Schiander GRAY
• 金额: $ 5.55万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-04 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10411081
• 关键词: Advanced Development; Area; Basic Science; Biological Markers; Bladder; CRISPR/Cas technology; Cancer Patient; Catchment Area; Chemicals; Clinic; Clinical; Clinical Sciences; Clinical Trials; Clinical Trials Network; Collaborations; Conduct Clinical Trials; Contrast Media; Core Facility; Development; Diagnosis; Doctor of Philosophy; Drug Combinations; Drug Delivery Systems; Evaluation; Fostering; Funding; Future; Goals; Head and neck structure; Health; Human; Institutes; Investigational Therapies; Investments; Label; Laboratories; Leadership; Lung; Malignant Neoplasms; Manuscripts; Medical; Medicine; New Agents; Peer Review; Pharmaceutical Chemistry; Phase; Prognosis; Program Development; Proteins; Publishing; Renal carcinoma; Research; Research Peer Review; Research Personnel; Schools; Science; Solid Neoplasm; Strategic Planning; Surgical margins; Talents; Technology; Testing; Therapeutic; Therapeutic Agents; Translating; Translational Research; Translations; United States National Institutes of Health; Universities; base; biomarker development; biomarker validation; cancer diagnosis; cancer therapy; cell free DNA; clinical application; clinical development; design; diagnostic biomarker; diagnostic strategy; drug development; drug discovery; experience; improved; innovation; malignant breast neoplasm; member; molecular diagnostics; molecular oncology; nanoimmunoassay; new technology; new therapeutic target; novel; novel diagnostics; novel strategies; novel therapeutics; oncology program; peer support; phase III trial; pre-clinical; programs; recruit; sensor; small molecule therapeutics; therapeutic biomarker; therapy outcome; tumor

PROJECT SUMMARY The Cancer Therapeutics (CT) Program has been reconfigured from the previous Molecular Oncology Program to unite an exciting new opportunity in drug development with ongoing research in the areas of biomarker design and new diagnostic approaches to cancer, the ultimate objective being the development of clinical trials with high impact for cancer patients with solid tumors. In conjunction with a University-wide initiative to enable drug discovery to improve human health, the Stanford Cancer Institute (SCI) Strategic Plan has made the discovery of new approaches to cancer treatment one of its major pillars. This new emphasis on drug development has been enabled by the recruitment of Nathanael Gray, PhD, co-leader of the program and a pre-eminent researcher in the development of novel therapeutic agents for cancer. Program co-leader, George W. Sledge, MD, has more than three decades of experience as a clinical trialist involved in Phase I, II, and III trials, including trials that have led to the FDA approval of new agents in breast cancer, as well as significant experience in the development of biomarkers for breast cancer. This complementary leadership team, in conjunction with a diverse and talented program membership, integrates highly relevant basic science research with the development and implementation of impactful clinical trials across the spectrum of solid tumors. With the addition of 24 new members since the last review, the 67 program members represent 3 schools and 18 departments across the University and are supported by peer-reviewed research totaling $10M, including 20 R01s. Peer-reviewed funding consists of $4.8M from the NCI, other NIH support amounts to $3.3M, and other peer-reviewed support to $1.8M. CT program members are highly motivated and interactive in their goal of bringing forward novel therapeutic options for cancer patients. Since 2015, members of the CT Program have published 814 manuscripts. Of these, 21% represent intra-programmatic, 42% represent inter-programmatic, and 95% represent multi-institutional collaborations. The SCI has fostered the CT Program by greatly expanding its potential through new recruitments, providing innovation fund support for new projects, as well as funds for retreats and seminars. SCI’s support has been instrumental in promoting intra- and inter-programmatic collaborations and in the planning and submission of two SPORE applications. The CT Program plans to accelerate investment in the discovery of new small molecule therapeutics, expand our clinical Early Drug Development Program, and pioneer high-impact clinical trials.

项目摘要 癌症治疗药（CT）计划已从先前的分子肿瘤计划重新配置 通过在生物标志物设计领域进行的持续研究，将激动人心的药物开发新机会结合在一起 和新的癌症诊断方法，最终目标是开发高的临床试验 对实体瘤癌症患者的影响。结合一项范围内的倡议，以启用毒品 发现改善人类健康的发现，斯坦福癌症研究所（SCI）战略计划已成为发现 癌症治疗的新方法之一。这种对药物开发的新强调已经 由Nathanael Gray，博士学位，该计划的共同领导者和杰出的杰出人物招募来启用 研究人员开发了新型癌症治疗剂。计划联合领导者乔治·W·斯莱奇（George W. Sledge）， MD，作为I，II和III阶段试验的临床试验列表，拥有超过三十年的经验，包括 导致FDA批准了乳腺癌方面的新药物的试验，以及在 开发用于乳腺癌的生物标志物。这个完整的领导团队与潜水员一起 和才华横溢的计划成员资格，将高度相关的基础科学研究与发展和 实施跨实体瘤范围的有影响力的临床试验。加上24个新 成员自上次审查以来，67个计划成员代表3所学校和18个部门 大学，并得到同行评审的研究，总计1000万美元，包括20个R01。同行评审 资金由NCI的480万美元组成，其他NIH支持为330万美元，以及其他经过同行评审的支持 至180万美元。 CT计划成员具有高度积极性和互动性，以提出小说 癌症患者的治疗选择。自2015年以来，CT计划的成员已发布814 手稿。其中，有21％代表截图，42％代表编程间，而95％ 代表多机构合作。 SCI通过大大扩展了CT计划 通过新招聘的潜力，为新项目提供创新基金支持，以及 撤退和下水道。 SCI的支持有助于促进组织内和截面 合作以及两个孢子应用程序的计划和提交。 CT计划计划 加速在发现新的小分子疗法的投资，扩展我们的临床早期药物 开发计划和先驱高影响力临床试验。